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Objectives This study was designed to evaluate the clinical and prognostic aspects of long QT syndrome (LQTS)-related car-
diac events that occur in the first year of life (infancy).
Background The clinical implications for patients with long QT syndrome who experience cardiac events in infancy have not
been studied previously.
Methods The study population of 3,323 patients with QT interval corrected for heart rate (QTc) 450 ms enrolled in the Inter-
national LQTS Registry involved 20 patients with sudden cardiac death (SCD), 16 patients with aborted cardiac arrest
(ACA), 34 patients with syncope, and 3,253 patients who were asymptomatic during the first year of life.
Results The risk factors for a cardiac event among 212 patients who had an electrocardiogram recorded in the first year
of life included QTc 500 ms, heart rate 100 beats/min, and female sex. An ACA before age 1 year was asso-
ciated with a hazard ratio of 23.4 (p  0.01) for ACA or SCD during ages 1 to 10 years. During the 10-year
follow-up after infancy, beta-blocker therapy was associated with a significant reduction in ACA/SCD only in
those with a syncopal episode within 2 years before ACA/SCD but not for those who survived ACA in infancy.
Conclusions Patients with LQTS who experience ACA during the first year of life are at very high risk for subsequent ACA or
death during their next 10 years of life, and beta-blockers might not be effective in preventing fatal or near-fatal
cardiac events in this small but high-risk subset. (J Am Coll Cardiol 2009;54:832–7) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.05.029M
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song QT syndrome (LQTS) is a rare genetic disorder
aused by mutations involving genes that encode critical
hannel pore-forming alpha subunits and channel interact-
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August 25, 2009:832–7 LQTS in the First Year of Lifeelayed ventricular repolarization seen as a prolonged QT
nterval on the electrocardiogram (ECG). Patients with this
isorder are at high risk of experiencing syncope, aborted
ardiac arrest (ACA), and sudden cardiac death (SCD)
1–4). Recent studies of LQTS indicate that risk factors for
xperiencing LQTS-related cardiac events are age- and
ex-related (1). The childhood (5), adolescent (6), and adult
7) periods have been described, but little is known about
he clinical course of LQTS patients who experience cardiac
vents during infancy (i.e., the first year of life).
The management of infants with symptomatic LQTS
onstitutes a serious clinical problem. It generates major
nxiety in the families and significant concerns among the
hysicians involved. The lack of data leaves considerable
ncertainty about the criteria for risk stratification and for
he attendant therapeutic strategies that should vary from
autious conservative management to more aggressive and
nvasive approaches.
The goals of the present study are to assess the clinical
isk factors for patients experiencing LQTS-related cardiac
vents (SCD, ACA, or syncope) in the first year of life and
o evaluate the subsequent clinical course of patients with an
nfantile expression of symptomatic LQTS (ACA or syn-
ope) during their next decade compared with those who
eached their first birthday without any LQTS-related
ardiac events.
ethods
he study population consisted of 3,323 patients drawn
rom the International LQTS Registry (8) who met the
ollowing criteria: LQTS probands and first- and second-
egree relatives of probands who had a QT interval cor-
ected for heart rate (QTc) 450 ms on a 12-lead ECG;
atients from LQTS families who were genotype positive
or an LQTS mutation regardless of their QTc interval; and
atients from LQTS families who were categorized as
aving SCD according to established Registry criteria (6)
ven if they did not have a recorded ECG. Infancy was
linical Characteristics of the Study Population in the First Year ofTable 1 Clinical Characteristics of the Study Population in the
Clinical Characteristics SCD
No. of patients 20
Female, n (%) 8 (40)†
Age at ECG, yrs 0.2 0.3†
No. of ECGs 8
QTc (ms) 549 55†
Family LQT1, n (%) 6 (30)
Family LQT2, n (%) 0 (0)
Family LQT3, n (%) 1 (5)
Genotype unknown (%) 65
Beta-blockers anytime, n (%) 5 (25)
Left cardiac sympathetic denervation, n (%) 1 (5)
Pacemaker, n (%) 1 (5)
Implanted cardioverter-defibrillator, n (%) 0 (0)10 of the 16 infants who had an aborted cardiac arrest (ACA) had a prior syncopal episode. †p  0.05
ECG  electrocardiogram; LQTS  long QT syndrome; QTc  QT interval corrected for heart rate; SCDefined as the period from birth
ntil age 1 year. Patients with the
ervell and Lange-Nielsen Syn-
rome, as determined by QTc
rolongation and congenital
eafness, were excluded from the
resent analysis, because their
nusually high risk during their
rst decade of life has already
een described (9,10). Of the
,323 patients who made up the
tudy population, there were
,253 subjects who had no his-
orical evidence of LQTS-related
ardiac events in the first year of
ife, and this group was used, by default, as the no cardiac
vent comparison group in infancy (Table 1).
The International LQTS Registry study was approved by
he University of Rochester Institutional Review Board, and
nformed consent was obtained from study participants. The
egistry included data on patients’ demographics, clinical
haracteristics, clinical history, information on LQTS-related
ardiac events, and therapy as described previously (8). Copies
f past ECGs were obtained at the time of enrollment, and
dditional ECGs, if available, were obtained at yearly follow-
p. The first recorded ECG was used for the current analysis.
azett’s formula was used to correct the QTc.
Patients were categorized into 1 of 4 LQTS groups:
) infants who had SCD and were from an identified LQTS
amily; 2) infants who had ACA; 3) infants who had a
yncopal event, defined as transient unexplained loss of
onsciousness during awake daily activity with abrupt onset
nd offset of the episode that was observed by a parent or an
dult supervising the infant; and 4) infants who did not have
n LQTS-related cardiac event. The primary outcome
uring ages 1 to 10 years among patients who experienced
CA, syncope, or no cardiac event in the first year of life
as a near-fatal or fatal cardiac event (ACA or SCD).
Abbreviations
and Acronyms
ACA  aborted cardiac
arrest
ECG  electrocardiogram
HR  hazard ratio
LQTS  long QT syndrome
QTc  QT interval
corrected for heart rate
SCD  sudden cardiac
death
SIDS  sudden infant
death syndrome
Year of Life
ACA* Syncope Only No. of Cardiac Events
16 34 3,253
11 (69) 22 (65) 2,014 (62)
3.5 5.5† 6.7 9.1† 29.4 21.4
16 33 3,155
45 65† 522 72† 489 47
0 (0) 7 (21) 806 (25)
4 (25) 7 (21) 679 (21)
1 (6) 1 (3) 173 (5)
69 55 49
12 (75)† 24 (71) 476 (15)
3 (19)† 2 (6)† 23 (0.7)
5 (31)† 1 (3) 36 (1)
3 (19)† 1 (3) 29 (0.9)versus No Cardiac Event.
 sudden cardiac death.LifeFirst
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LQTS in the First Year of Life August 25, 2009:832–7Statistical analysis involved the t test for continuous
ariables and chi-square or Fisher exact tests for categorical
ariables. Follow-up time after the first year of life was
ensored at 10 years of age because of the limited number of
atients who experienced cardiac events beyond that age.
he graphical Kaplan-Meier method and the Cox propor-
ion hazards model were used to evaluate the risk of
re-specified clinical factors of interest to cardiac events
uring ages 1 to 10 years. Time-dependent syncope and
ime-dependent beta-blocker use were included in the Cox
odels. Relevant interactions among the risk variables and
utcome were explored in the Cox models. All models were
tratified by the decade in which the patient was born
before 1970, 1970 to 1980, 1980 to 1990, or after 1990) to
ccount for differences in the baseline hazard function for
istorically different time periods in which different LQTS-
elated therapies were used. The statistical software used to
erform the analyses was SAS version 9.1.3 (SAS Institute,
ary, North Carolina). All statistical tests were 2-sided, and
he significance level was set at p  0.05.
esults
QTS during infancy (ages 0 to 1 year). In the study
opulation of 3,323 LQTS subjects, 20 died suddenly, 16
xperienced ACA, and 34 experienced syncope in the first
ear of life; the remaining 3,253 subjects had no evident
QTS-related symptoms before their first birthday. The
linical characteristics of the 4 groups of patients are
resented in Table 1.
Descriptive characteristics of the 20 patients who died
uddenly during the first year of life are presented in Table 2.
escriptive Characteristics of the 20 LQTS Infants Who Died in theTable 2 Descriptive Characteristics of the 20 LQTS Infants Wh
Patient #
Sex
(Yr of Birth)
Age at Death
(Days)
QTc
(ms)
RR Interval
(ms)
P
1 F (1985) 176 560 420
2 M (1987) 193 500 460
3 M (1991) 352 600 440
4 F (1991) 79 620 600
5 M (1945) 5 — —
6 F (1960) 1 — —
7 F (1978) 75 — —
8 M (1957) 312 — —
9 M (1962) 122 — —
10 M (1997) 1 500 780
11 M (1999) 3 — —
12 F (1992) 33 610 720
13 M (1953) 2 — —
14 F (1955) 60 — —
15 M (1970) 93 — —
16 M (1967) 120 — —
17 M (1993) 47 — —
18 F (1992) 88 500 360
19 M (1999) 326 500 530
20 F (1999) 60 — —he 3 infants who had neither an ECG nor a parental ECG were first-degree relatives of family members
BB  beta-blockers; LCSD  left cardiac sympathetic denervation; PM  pacemaker; other abbreviatiight (40%) of the patients were female, and all 8 who
ad an ECG had a QTc 500 ms. Data were available
or at least 1 parent’s QTc in 15 patients, and 10 of 15
atients had a parent with a QTc 450 ms. Four of the
0 infants with SCD experienced a prior cardiac event
efore death, and 4 patients were receiving beta-blockers
t the time of death. One patient who died was treated
ith a pacemaker, left sympathetic denervation, and
eta-blockers.
The distribution of risk factors for the different cardiac
vent groups for the 212 patients who had an ECG during
he first year of life are presented in Table 3. Cox propor-
ional hazard regression analysis revealed that the following
isk factors were associated with a cardiac event in infancy
n  28; SCD, ACA, or syncope only): QTc 500 ms
hazard ratio [HR]: 4.31, p  0.002), RR 600 ms (HR:
.38, p  0.04), and female sex (HR: 2.21, p  0.05). Age
t ECG; beta-blocker at time of ECG; and LQT1, LQT2,
nd LQT3 genotypes did not make significant contributions
o the risk model.
linical course during ages 1 to 10 years. The clinical
ourse of patients who experienced ACA, syncope, or no
ardiac event in the first year of life was evaluated during
he next 10 years of life. Those who experienced ACA in
he first year had a significantly higher probability of
xperiencing another ACA event or an LQTS-related
CD during ages 1 to 10 years (Fig. 1). An ACA in the
rst year of life was associated with an HR of 23.4 (p 
.01) for a subsequent ACA/LQTS-related SCD during
he 1- to 10-year period (Table 4). However, syncope
nly during infancy was not associated with an increased
t Year of Lifed in the First Year of Life
Max QT
s)
Prior Syncope
(n)
Prior ACA
(n) Treatment(s)
0 1
0 0 3 BB
0 0 2 BB, PM, LCSD
0 0 0 BB
0* 0 0
0 0 0
0 0
0 0
0 0 0
0* 0 0
0* 0 0
0 0 0 BB
0 0 0
0* 0 0
0 3 0
0 0 0
0 0
0 0
0 0 0 BB (discontinued before death)
0 0 0Firso Die
arent*
(m
—
44
42
47
49
48
—
—
58
50
40
49
45
45
41
43
—
—
49
50with well-documented LQTS. *Only mother’s QTc recorded.
ons as in Table 1.
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August 25, 2009:832–7 LQTS in the First Year of Lifeisk for ACA/LQTS-related SCD during follow-up.
ecent syncope within the previous 2 years, QTc 500
s, and male sex were significant risk factors for ACA/
QTS-related SCD in the follow-up period. Beta-
locker use was not associated with a significant reduc-
ion in ACA/LQTS-related SCD risk during 10-year
ollow-up (Table 4). In interaction analyses, beta-blocker
herapy was associated with a significant reduction in
hese events in those with a syncopal episode within 2
ears before ACA/SCD (HR: 0.35, p  0.03, 95%
onfidence interval: 0.14 to 0.90) but not for those with
linical Characteristics of Patients With an ECG in the First Year oTable 3 Clinical Characteristics of Patients With an ECG in the
Clinical Characteristic Sudden Cardiac Death
No. of patients 8
Female, n (%) 4 (50)
Age at ECG, yrs 0.2 0.3
Beta-blocker at time of ECG, n (%) 0 (0)
QTc (ms) 549 55*
QTc 500 ms, n (%) 8 (100)*
RR (ms) 538 150
RR 600 ms, n (%) 3 (38)*
Family LQT1, n (%) 2 (25)
Family LQT2, n (%) 0 (0)
Family LQT3, n (%) 1 (13)
p  0.05 versus No Cardiac Event in the first year of life.
Abbreviations as in Table 1.
Figure 1 Cumulative Probability of ACA/LQTS-Related Death
Cumulative probability of aborted cardiac arrest (ACA)/long QT syndrome (LQTS)-re
during ages 1 to 10 years among those with ACA, syncope, or no cardiac event (Cemote syncope more than 2 years before or ACA in
nfancy.
Because of the increased long-term risk associated with
CA that occurred in the first year of life (Table 4), we
ompared the risk of ACA in the first year of life with the
isk of a first ACA after age 1 year for second ACA or
QTS-related SCD during ages 1 to 10 years. Infants who
ad an ACA in the first year of life had a 2.3-fold greater
isk (p  0.03) for a second ACA or SCD during ages 1 to
0 years than patients who experienced their first ACA after
ge 1 (Table 5).
t Year of Life
ACA Syncope Only No. of Cardiac Events
6 14 184
4 (67) 8 (57) 86 (47)
0.2 0.3 0.2 0.2 0.2 0.3
1 (17) 3 (21) 20 (11)
588 58* 534 74* 491 48
5 (83)* 7 (50) 65 (35)
723 151* 561 195 496 111
5 (83)* 1 (7) 16 (9)
0 (0) 5 (36) 63 (34)
1 (17) 4 (29) 43 (23)
1 (17) 0 (0) 11 (6)
eath
he first year of life.f LifeFirslated d
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his International LQTS Registry study with a focus on
ardiac events occurring in the first year of life and on the
rognostic significance of these events to age 10 years has
rovided 4 major findings. Infants with QTc prolongation,
elative slow heart rate, and female sex are at increased risk
or cardiac events during the first year of life. The LQTS
nfants who experience ACA in the first year of life were at
ery high risk for near-fatal or fatal cardiac events during the
ext 10 years of life. Syncope in infancy was not a major risk
actor for subsequent ACA/SCD during ages 1 to 10 years,
ut this negative finding might relate to the difficulty
arents have in accurately recalling or identifying a syncopal
pisode with transient loss of consciousness in their infant
hild. For infants who survive the first year of life, we found
o statistical evidence of an association between the use of
eta-blockers and reduction in ACA or LQTS-related
CD during the next decade of life. These results carry
ignificant clinical implications and provide previously un-
vailable data to help physicians make rational choices for
he management of LQTS infants with syncope and ACA
n the first year of life.
Goldenberg et al. (5) showed that time-dependent beta-
locker therapy was associated with a significant 53%
eduction in the risk of ACA or LQTS-related SCD during
ges 1 to 12 years. Goldenberg’s study did not include
nfants who experienced ACA in the first year of life. In the
ultivariate Analysis: Predictors of ACA or LQTS-Related Sudden DTable 4 Multivariate Analysis: Predictors of ACA or LQTS-Relat
Factor
No. of First Cardiac Event
[ACA/SCD] in Patients
With the Specific Factor
ACA in first yr of life (n  16) 8 [6/2]
Syncope in first yr of life (n  44) 7 [4/3]
1 syncope in the past 2 yrs* 24 [20/4]
1 syncope more than 2 yrs ago and
no syncope within the past 2 yrs*
4 [3/2]
QTc 500 ms (n  1,062) 38 [26/12]
Male (n  1,256) 38 [27/11]
his analysis involves only patients who survived the first year of life and includes 99 patients with “
vent/unit of time with the factor present to the risk for patients with the factor absent. The numbe
ere 58 first cardiac events consisting of 42 ACAs and 16 LQTS-related SCDs. Time-dependent bet
ut was included as a factor in the multivariate analysis; 559 patients were receiving beta-blocker
yncope more than 2 years ago are time-dependent factors with patients moving into and out of e
isk factors cannot be provided as simple raw number counts for these time-dependent variables
CI  confidence interval; other abbreviations as in Table 1.
ultivariate Analysis: Predictors for Second ACA orQTS-Rel d Death During Age 1 to 10 Years byirs ACA in the First Year of Life Versus First ACAges 1 to 10 Y r
Table 5
Multivariate Analysis: Predictors for Second ACA or
LQTS-Related Death During Ages 1 to 10 Years by
First ACA in the First Year of Life Versus First ACA
Ages 1 to 10 Years
Factor Hazard Ratio 95% CI p Value
First ACA in the first yr of life 2.3 1.1–4.8 0.03
QTc 500 ms 2.3 0.9–5.5 0.07
Male 0.9 0.4–2.0 0.7
Tc 500 ms and male sex were included in this model in view of their contribution to cardiacp
vents in Table 4.
Abbreviations as in Tables 1 and 4.urrent study, beta-blockers were associated with a 65%
eduction in 1- to 10-year cardiac events in those who had
ecent syncope (i.e., within 2 years of the end point) but not
or patients who experienced ACA in infancy.
In a study of LQTS neonates and children, Villain et al.
11) reported an overall favorable outcome for children
reated with beta-blocker therapy. Direct comparison with
ur study is difficult, because their definition of neonates
xtended only to the first 6 months. However, there were 2
eaths in patients receiving beta-blocker therapy, and they
nvolved 2 infants with complete atrioventricular block who
ied at 3 and 9 days of age after a pacemaker implant and
elated complications. Sixteen children required—in agree-
ent with our findings—additional therapies because of
nsufficient protection from beta-blocker therapy for cardiac
vents, and 10 of these 16 children had symptoms in the
rst year of life.
Beta-blockers are currently first-line therapy for patients
ith symptomatic LQTS (12,13), but they are not always
ffective in the young (14). Nevertheless, beta-blockers
hould be initiated in all infants with LQTS unless a specific
ontraindication exists such as asthma or an allergy to this
lass of drugs. Infants who survive an ACA are potential
andidates for an implanted defibrillator (15), but this
herapy is rarely used in very young patients, because of the
otential complications associated with device implantation
n small subjects. Pacemakers (16) and left cardiac sympa-
hetic denervation (17–19) have been used in young high-
isk LQTS patients, but these therapies as well as implanted
efibrillators were used infrequently in the study population,
nd thus there was insufficient statistical power to properly
valuate their efficacy in this age group. Nevertheless, the
eported high success rate of left cardiac sympathetic dener-
ation in LQTS in older patients (19) and its feasibility in
nfants (20,21) provides a rationale for considering this
ntervention together with beta-blocker therapy as a logical
rst step for therapy in high-risk infants who have experi-
nced an ACA event. This therapeutic approach does not
During Ages 1 to 10 Yearsdden Death During Ages 1 to 10 Years
Hazard Ratio 95% CI p Value
23.4 7.6–71.9 0.01
0.7 0.2–2.5 0.58
9.7 5.2–18.0 0.01
1.6 0.5–5.4 0.47
3.4 1.9–6.0 0.01
2.2 1.3–3.9 0.01
ECGs” who had only 2 deaths during the 10-year follow-up. The hazard ratio is the risk of a cardiac
ackets refer to the number of patients with the factor present. During the 10-year follow-up, there
er did not make a significant main-effect contribution to this model (hazard ratio: 0.71, p  0.30)
time or another during the 1- to 10-year follow-up. *Syncope within the past 2 years and remote
hese risk groups over time during the 1- to 10-year follow-up. The numbers of patients with theseeathed Su
s
Missing
rs in br
a-block
s at one
ach of treclude the possibility of an implanted defibrillator later
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August 25, 2009:832–7 LQTS in the First Year of Lifen, if necessary, when the child is older and is of sufficient
ize for defibrillator implantation.
Long QT syndrome in the first year of life is of special
nterest, because of its association with sudden infant death
yndrome (SIDS), and newborn ECG screening has been
sed to identify these at-risk patients (22,23). The risks and
enefits of such a diagnostic approach have been discussed
n a recent editorial by Berul and Perry (24). In a large
rospective study looking at the mechanism of SIDS,
rnestad et al. (25) genotyped SIDS victims for LQTS
utations and estimated that LQTS was the cause of at
east 9.5% of SIDS cases. Currently, it is cost-prohibitive to
outinely genotype every newborn for LQTS mutations, but
t is advisable to genotype newborns in LQTS families and
ewborns found to have a clear QT prolongation during an
CG screening performed for whatever reason.
tudy limitations. Limitations in the present study are the
bsence of ECGs in 60% of those who died in infancy, the
imited numbers of infants who received therapy of any kind
efore SCD in the first year of life, and the incomplete
enotyping of the study population. The goal of the present
tudy was to evaluate all LQTS probands and affected first-
nd second-degree relatives of LQTS probands during the
rst year of life in the International LQTS Registry.
estriction of the study population only to those with
CGs before cardiac events in infancy, those with therapy,
nd patients with genotype data would have provided an
ncomplete picture of the severity of the disease process in
nfancy. We cannot draw any conclusions about the impact
f preventive therapy on SCD in infants with LQTS. In
iew of the low event counts, the findings from this study
eed to be interpreted with caution, because over-fitting
ight be an issue.
onclusions
ong QT syndrome patients who experience ACA during
he first year of life comprise a small (2%) but very-high-
isk group for subsequent near-fatal and fatal cardiac events
uring the first decade of life. These high-risk patients
equire aggressive age-related treatment and careful
ollow-up to reduce their LQTS-related morbidity and
ortality.
eprint requests and correspondence: Dr. Arthur J. Moss, Heart
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